Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bernard Zinman

Showing results (41-50 of 391) with videos related to

Pageof 40
Sort By:
International Journal of Obesity (2005)|March 12, 2026
The effects of time-restricted eating on energy balance regulation in adults with overweight/obesity and type 2 diabetesCaroline K Kramer, Bernard Zinman, Denice S Feig, et al.
Diabetologia|August 2, 2018
Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trialNaveed Sattar, David Fitchett, Stefan Hantel, et al.
The Lancet. Diabetes & Endocrinology|August 14, 2025
The central role of recovery of β-cell function in the remission of prediabetes: a prospective cohort study in CanadaRavi Retnakaran, Jiajie Pu, Junwei Shen, et al.
Diabetes Care|September 25, 2014
Liraglutide and the preservation of pancreatic β-cell function in early type 2 diabetes: the LIBRA trialRavi Retnakaran, Caroline K Kramer, Haysook Choi, et al.
American Journal of Physiology. Endocrinology and Metabolism|November 30, 2017
Effect of chronic liraglutide therapy and its withdrawal on time to postchallenge peak glucose in type 2 diabetesSusan Tran, Caroline K Kramer, Bernard Zinman, et al.
Diabetes Research and Clinical Practice|May 21, 2014
Emerging parameters of the insulin and glucose response on the oral glucose tolerance test: reproducibility and implications for glucose homeostasis in individuals with and without diabetesCaroline Kaercher Kramer, Vladimir Vuksan, Haysook Choi, et al.
Diabetes, Obesity & Metabolism|June 28, 2023
Baseline determinants of remission of type 2 diabetes in response to short-term insulin-based therapy: The pivotal role of beta-cell functionRavi Retnakaran, Jiajie Pu, Alexandra Emery, et al.
Diabetes, Obesity & Metabolism|January 30, 2018
Two-year trial of intermittent insulin therapy vs metformin for the preservation of β-cell function after initial short-term intensive insulin induction in early type 2 diabetesRavi Retnakaran, Haysook Choi, Chang Ye, et al.
Nature Communications|October 16, 2022
The metabolic effects of adding exenatide to basal insulin therapy when targeting remission in early type 2 diabetes in a randomized clinical trialRavi Retnakaran, Chang Ye, Alexandra Emery, et al.
Diabetes Care|August 16, 2022
Association of Estimated Time-in-Range Capillary Glucose Levels Versus HbA1c With Progression of Microvascular Complications in the Diabetes Control and Complications TrialJohn M Lachin, Ionut Bebu, Xiaoyu Gao, et al.
Pageof 40

Showing results (41-50 of 391) with videos related to

Sort By:
Pageof 40
International Journal of Obesity (2005)|March 12, 2026
The effects of time-restricted eating on energy balance regulation in adults with overweight/obesity and type 2 diabetesCaroline K Kramer, Bernard Zinman, Denice S Feig, et al.
Diabetologia|August 2, 2018
Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trialNaveed Sattar, David Fitchett, Stefan Hantel, et al.
The Lancet. Diabetes & Endocrinology|August 14, 2025
The central role of recovery of β-cell function in the remission of prediabetes: a prospective cohort study in CanadaRavi Retnakaran, Jiajie Pu, Junwei Shen, et al.
Diabetes Care|September 25, 2014
Liraglutide and the preservation of pancreatic β-cell function in early type 2 diabetes: the LIBRA trialRavi Retnakaran, Caroline K Kramer, Haysook Choi, et al.
American Journal of Physiology. Endocrinology and Metabolism|November 30, 2017
Effect of chronic liraglutide therapy and its withdrawal on time to postchallenge peak glucose in type 2 diabetesSusan Tran, Caroline K Kramer, Bernard Zinman, et al.
Diabetes Research and Clinical Practice|May 21, 2014
Emerging parameters of the insulin and glucose response on the oral glucose tolerance test: reproducibility and implications for glucose homeostasis in individuals with and without diabetesCaroline Kaercher Kramer, Vladimir Vuksan, Haysook Choi, et al.
Diabetes, Obesity & Metabolism|June 28, 2023
Baseline determinants of remission of type 2 diabetes in response to short-term insulin-based therapy: The pivotal role of beta-cell functionRavi Retnakaran, Jiajie Pu, Alexandra Emery, et al.
Diabetes, Obesity & Metabolism|January 30, 2018
Two-year trial of intermittent insulin therapy vs metformin for the preservation of β-cell function after initial short-term intensive insulin induction in early type 2 diabetesRavi Retnakaran, Haysook Choi, Chang Ye, et al.
Nature Communications|October 16, 2022
The metabolic effects of adding exenatide to basal insulin therapy when targeting remission in early type 2 diabetes in a randomized clinical trialRavi Retnakaran, Chang Ye, Alexandra Emery, et al.
Diabetes Care|August 16, 2022
Association of Estimated Time-in-Range Capillary Glucose Levels Versus HbA1c With Progression of Microvascular Complications in the Diabetes Control and Complications TrialJohn M Lachin, Ionut Bebu, Xiaoyu Gao, et al.
Pageof 40